PRF Technologies’ Ropivacaine-Only PRF-110 Matches 72-Hour Analgesia Benchmark
PRFX•PRF-110 delivered ropivacaine-only, NSAID-free analgesic relief comparable to ZYNRELEF over a 72-hour post-surgical period in a head-to-head pig study. The oil-based extended-release formulation maintained efficacy with no unexpected safety findings, leveraging ropivacaine’s lower cardiac toxicity versus bupivacaine.
1. Head-to-head Preclinical Results
In a validated pig incisional pain model, PRF-110 delivered a single wound-bed administration and matched ZYNRELEF’s analgesic efficacy over 72 hours based on behavioral and stimulus-evoked pain metrics.
2. Formulation and Safety Profile
PRF-110’s ropivacaine-only, NSAID-free oil-based extended-release solution exhibited sustained local analgesia with no unexpected tolerability issues, leveraging ropivacaine’s lower cardiac toxicity compared to bupivacaine.
3. Development Path and Implications
Positive comparative data supports strategic planning for clinical trials and regulatory engagement, positioning PRF-110 as a potential non-opioid post-operative pain management option.
